

Wed 24 September 2014

<b>Session: Success Stories (5) and keynote. CHAIR: Michael Hennig</b>			
<b>08:30</b>	Nick Skelton	Genentech	Combining fragments with lead-like compounds: Discovery and efficient optimisation of novel Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors
<b>08:50</b>	Martin Scanlon	Monash univ, Melbourne	Inhibition of oxidative protein folding as an approach to target bacterial virulence
<b>09:10</b>	Maurizio Pellechia	Sanford Burnham	Protein NMR to guide FBLD targeting PPIs
<b>09:30</b>	Ramon Campos-Olivas	CNIO Madrid	Discovery of selective ligands for telomeric RNA G-quadruplexes (TERRA) through <sup>19</sup> F-NMR based fragment screening
<b>09:50</b>	Daniel Wyss	Merck	Discovery and optimisation of a series of pyrimidine PDE10A inhibitors enabled by fragment screening, structure-based design and parallel synthesis
<b>10:10</b>	COFFEE		
<b>11:00</b>	Derek Lowe	Vertex	<b>Keynote lecture:</b> Is it different this time? FBDD's place in pharma
<b>12:00</b>	CONFERENCE CLOSES		